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Abstract The total peroxyl radical scavenging capacity 
(TRAP) of human plasma was measured from pneumonia 
patients and controls. TRAP and its main components, ascorbic 
acid, alpha-tocopherol, uric acid or protein thiol groups, were 
unaltered, but the concentration of unidentified antioxidants in 
pneumonia patients was significantly reduced. Our results 
indicate that human plasma may contain so far unidentified 
antioxidants depleted in infection. 
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1. Introduction 
It is commonly assumed that an effective defence against 
bacterial infection requires release of active oxygen species 
during the neutrophil respiratory burst. This may play an 
important role in causing damage to host tissues [1]. The 
polymorphonuclear neutrophil (PMN) has a complex enzyme 
system that reduces oxygen to superoxide (02)  [2]. Both O~- 
and H202 can be detected after the PMN is activated and a 
substantial fraction of H202 is consumed by myeloperoxidase 
to produce hypochlorous acid (HOC1) [3]. HOC1 is a potent 
oxidant which reacts readily with biological molecules. It is 
cytotoxic to a wide variety of mammalian cells [4]. Since 
HOC1 can account for at least 40% of the 02  generated 
during the respiratory burst [5], it may be responsible for 
most of the oxidant damage mediated by neutrophils [6]. 
In plasma, stimulated polymorphonuclear leukocytes initi- 
ate very rapid oxidation of ascorbate, followed by partial 
depletion of urate [7]. It has been proposed that plasma 
thiol-groups (which are known to be largely located on albu- 
min) are in quantitative terms the most important scavengers 
of HOC1 [8]. However, if extra ascorbate is added to plasma, 
ascorbic acid becomes the most important scavenger of HOC1 
[8]. Plasma ascorbic acid is known to decrease in acute pan- 
creatitis and other intra-abdominal crises [9], and urine ascor- 
bic acid concentration decreases during a common cold 
[10].This study set out to explore the effect of acute infection 
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upon plasma antioxidant defences in a case-control design 
involving hospitalized pneumonia patients. 
2. Materials and methods 
Sixteen hospitalized pneumonia patients were studied from the De- 
partment of Infectious Diseases of Tampere City Hospital. Sixteen 
controls were matched by age, gender and other disease. The mean 
age of the patients (10 male and 22 female) was 66.4 years (range 33- 
85), and the mean age of the controls (10 male and 22 female) was 
65.8 (range 33-85 years). The diagnosis of pneumonia was based on 
clinical symptoms and laboratory evidence of infection, increased 
CRP and ESR, a new or progressive infiltrate on the chest X-ray 
and response to antibiotic therapy. Urine creatinine clearance was 
normal in all patients. The pneumonia patients received penicillin G 
(1-2 mill. IU four times/day intravenously) orcefuroxime (750 mg-l.5 
g three times/day intravenously). None of them was given 02 treat- 
ment during the experiment. The diet was standardized hospital food. 
2.1. The plasma sample 
All blood samples were collected within 1-3 days (mean 2.3) of the 
diagnosis of pneumonia. The samples of venous blood were drawn 
from the antecubital vein into precooled EDTA-containing Vacutai- 
ner tubes. The samples were placed in an ice bath, protected from 
light and immediately transported to the laboratory where the plasma 
was separated by centrifugation. The plasma samples were stored in 
liquid nitrogen until analyzed. For ascorbic acid determination, a 
special tube containing meta-phosphoric a id (5% final concentration) 
was prepared. 
Total peroxyl antioxidant capacity (TRAP) was determined by the 
chemiluminescence m thod, which is described in full detail elsewhere 
[11]. Briefly, constant production of peroxyl radicals by ABAP (2,2'- 
azobis [2-amidinopropane] hydrochloride) is followed by luminol-en- 
hanced chemiluminescence. The time for which the added test sample 
extinguishes the reaction is directly proportional to the peroxyl radi- 
cal-trapping antioxidant capacity of the sample [11,12]. TRAP is thus 
expressed as micromoles of peroxyl radicals trapped by one litre of the 
sample. 
In addition to direct measurement of TRAP (TRAPmeas), calcu- 
lated TRAP (TRAPcalc) was derived from the concentrations of in- 
dividually measured antioxidants in plasma with experimentally de- 
termined stoichiometric factors [11,12]: For protein SH-groups the 
stoichiometric factor was 0.4, for ascorbic acid 0.7, for uric acid 
and for tocopherol 2.0. Thus TRAPcalc = 2.0 X (tocopherol concen- 
tration) + 2.0 X (uric acid) + 0.7 x (ascorbic acid) + 0.4 X (SH-groups). 
The percentage contribution of individual components was calculated 
from total TRAPmeas. The difference between measured TRAP and 
calculated TRAP (TRAPmeas - TRAPcalc = UNID) represents he 
antioxidative capacity of as yet unidentified antioxidants. 
For the evaluation of the method of analysis, artificial plasma was 
prepared by mixing the known antioxidants of plasma (urate, -SH 
groups of GSH, ascorbic acid and Trolox) in different concentrations 
with the assay buffer as described elsewhere [13]. The correlation 
between measured and calculated TRAP was linear, as shown earlier 
[13], especially in cases where the theoretical TRAP was similar to 
that of human plasma (>700 gmol/1). This strongly suggests not only 
that the stoichiometric factors are highly accurate, but also that there 
is no recycling or regeneration of the components. 
The concentrations of uric acid and ascorbic acid were measured by 
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HPLC with an electrochemical detector according to the method of 
Frei et al. [14]. Alpha-tocopherol was determined by the modified 
HPLC method [15]. The protein SH-groups were determined accord- 
ing to Ellman [16]. 
The method of whole blood chemiluminescence (CL)has been de- 
scribed earlier [17]. Briefly, cold suspensions of reagents and antico- 
agulated blood (EDTA) were mixed. CL emission was measured at 
37°C for 60 min in a 500 ~tl HBSS buffer containing 4× 10 -4 M 
luminol (Sigma), 0.1% gelatin, 1 mg of opsonized zymosan (Sigma) 
and 50, 100 or 200 nanoliters of blood, using an automated lumin- 
ometer setup (LKB Wallac 1251 Luminometer connected to a PC). 
Maximum CL, (usually obtained 25 min after reaction onset) was 
plotted against each blood sample volume and expressed asmV/ktl. 
2.2. Statistics 
Data analysis i  based on analysis of variance and analysis of var- 
iance for repeated measures. Multiple regression analysis and Stu- 
dent's t-test were also used. All results are given as means _+ S.E.M. 
The study protocol was approved by the Ethical Committee of 
Tampere City Hospital. 
3. Results 
The total peroxyl radical scavenging capacity of plasma 
(TRAP) decreased in a non-significant way in the patient 
group. Among the known components of TRAP (uric acid, 
ascorbic acid, tocopherol, SH-groups) no difference was de- 
tected in mean plasma concentrations. However, a highly sig- 
nificant (P < 0.0001) difference was found in the amount of 
unidentified antioxidants between the patient and control 
group (299+30.8 ktmol/1 versus 506_+25.8 ktmol/1). All the 
plasma concentrations are shown in Table 1. 
As an indicator of infection, the chemiluminescence (CL) 
produced by polymorphonuclear leukocytes (PMN) was sig- 
nificantly (P = 0.0186) higher in the patient group, 
180.2_+34.4 mV/~tl, compared with the control value, 
108.8+6.5 mV/~tl. The mean leukocyte concentration was 
7.01 -+0.67 E9/I in the patient group and 5.89-+0.65 E9/1 in 
the control group. 
4. Discussion 
The purpose of this study was to follow the changes occur- 
ring in the total peroxyl scavenging capacity of human plasma 
in a state of increased radical production (e.g. acute infection). 
The most important finding with regard to plasma ntioxidant 
defences was the sharp decrease in the amount of unidentified 
antioxidants of human plasma in the patient group. No other 
significant changes were seen in plasma antioxidant values, 
although the TRAP concentration i  the patient group was 
lower than in the controls. Uric acid increased non-signifi- 
cantly in the patient group, probably because of ischemia. 
Previous results indicate that an increase in uric acid concen- 
tration results in increased TRAP concentration, without his 
affecting the amount of unidentified antioxidants [18]. Vitamin 
C levels were low in both groups. Low vitamin C intake is a 
typical finding in the Finnish population, especially in males 
and older age groups [19]. 
Several earlier studies attest o the usefulness of TRAP in 
evaluating extracellular fluid antioxidant ability [13,18,20]. 
Among the different components of TRAP, the proportion 
of unidentified antioxidants in human plasma in this study 
was 28% in the patient group and 42% in the control group. 
The latter figure is consistent with earlier findings [13,18]. 
There are different ways in which the observed existence of 
unidentified antioxidants in human plasma can be explained. 
One possible explanation lies in the methodology applied. 
Stoichiometric factors used for the identified components of 
TRAP could be too low, or recycling or regeneration of the 
components could occur. However, considering our results 
with artificial plasma, we have shown that this is not the 
case [13,21]. The mean difference between TRAP measured 
and calculated by the stoichiometric factors for individual 
components was only about 80 ~mol/1, which indicates that 
not only are the factors very precise, but also that there is no 
recycling or regeneration f the components. Our earlier esult 
clearly showed that the stoichiometric factor of ascorbic acids 
(AA) is concentration-dependent [13].In cerebrospinal fluid 
(CSF), where the AA concentration is 8-10 × higher than in 
plasma, the stoichiometric factor was three times lower [13]. 
Earlier studies have drawn attention to similar phenomena, 
indicating a concentration-dependent radical trapping capabil- 
ity in ascorbate [14,20]. However, in concentrations occurring 
in plasma the stoichiometric factor is in the range of 0.64).8 
[ll,13]. 
Other compounds such as bilirubin, 13-carotene and flavo- 
noids have been proposed to act as antioxidants in vivo and 
Table 1 
Plasma mean concentrations (p.mol/1) of TRAP and its components in the patient and control group 
Group Mean + S.E. n 
TRAP patients 1065 + 71.8 16 
controls 1201 + 42.8 16 
Uric acid patients 278 + 25.5 16 
controls 242 + 17.7 16 
SH-groups patients 391 + 19.6 16 
controls 381 + 19.9 16 
Ascorbic acid patients 32 _+ 2.9 16 
controls 33 + 4.7 16 
Alpha-tocopherol patients 15 + 1.2 16 
controls 17 + 1.8 16 
UNID patients 299 + 30.8*** 16 
controls 506 + 25.5 16 
UNID = unidentified antioxidants, ***P < 0.0001. 
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could be one part of UNID.  However, Lindeman et al. [22] 
have shown that by recalculating the proport ion of bilirubin 
from TRAPcalc (using a stoichiometric factor of 2.0) its per- 
centage contribution is less than 4%. Also, the plasma con- 
centration of t-carotene is too low to make a significant con- 
tribution to TRAPcalc [22]. Our preliminary data show that 
flavonoids have a minor contribution (less than 1%) to TRAP 
(Mets/i-Ketel/i et al. unpublished ata) and they cannot be 
responsible for the large proportion of UNID.  We propose 
that human plasma contains one or more important peroxyl 
radical trapping antioxidants that as yet remain unidentified. 
Earlier results from our laboratory indicate that this UNID 
may be induced by oxidative stress such as severe preeclamp- 
sia [18]. 
The patients in this study were treated with either penicillin 
G or cefuroxime. Earlier data suggest hat cephalosporines, 
ampicillin and piperacillin are capable of inhibiting the neu- 
trophil-mediated lysis of target cells, while penicillin G is in- 
effective [23]. Cephalosporines are proposed to be scavengers 
of HOC1 at therapeutically relevant concentrations [24]. How- 
ever, in our study the patient group showed a significant de- 
crease in the amount of unidentified antioxidants, and the 
possible beneficial effect of cephalosporines did not protect 
the antioxidant defence system against the HOC1 increase. 
This study showed that in acute infection the amount of 
classical antioxidants remains unchanged, whereas the amount 
of unidentified antioxidants decreases. 
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